This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.

Clinical trial NCT07028853 · RECRUITING

Trial details

NCT number: NCT07028853
Sponsor: Pfizer
Status: RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Metastatic Castration Sensitive Prostate Cancer (mCSPC)Hormone Sensitive Prostate Cancer Prostate Cancer Cancer of the Prostate

Start date: 2025-09-28
Primary completion: 2028-09-12
Enrollment: 1000

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.